Jefferies analyst Brian Tanquilut raised the firm’s price target on Cardinal Health (CAH) to $125 from $110 and keeps a Hold rating on the shares. The recent GI Alliance, Integrated Oncology Network, and Specialty Networks deals are good moves for Cardinal Health, though Advanced Diabetes Supply serves a different purpose and Jefferies would be more cautious on Continuous Glucose Monitoring distribution, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Cardinal Health Expands with $2.9 Billion Fundraising
- Cardinal Health Expands with Strategic Acquisitions
- Cardinal Health announces strategic acquisitions to its portfolio
- Cardinal Health price target raised to $127 from $119 at Morgan Stanley
- Cardinal Health price target raised to $124 from $119 at Deutsche Bank